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Biomarkers are measurable substances which could monitor the state of biological 
processes, pathogenic processes, or pharmacologic responses. Thus, the detection of biomarkers 
is important to diagnosis, clinical endpoint measurement and disease process measurement. 
Antibodies are proteins which bind to specific substances, their antigens, through variable 
regions. Thus, antibodies provide an unlimited natural resource for detecting almost any 
biomolecules and their modifications as a sensor domain. Immunoassays such as RIA and 
ELISA are wide-used in biomarker detection with high sensitivity and high specificity. 
However, these immunoassays usually require several rounds of incubation and washing steps 
including tedious manipulations, which make them difficult to apply to point of care detection. 
In addition, conventional immunoassays are not able to trace the dynamic change of protein 
modifications in living cells or living organisms. 
Förster resonance energy transfer (FRET) between GFP variants, are widely used to 
monitor biological phenomena and biomolecular modification. FRET efficiency is affected by 
the distance and orientation of fluorescence donor and fluorescence acceptor. Therefore, it could 
be used to monitor the spatial relationships or conformation changes of interesting molecules. A 
novel immunoassay based on the interchain interaction of antibody variable region, Open 
sandwich ELISA, was performed to be a powerful method to quantify low molecular weight 
antigens. In order to reduce the manipulate of heterogeneous immunoassay, homogeneous 
immunoassay which using antibody V region as a sensor and a fluorescent protein pair as a 
reporter was established and was named after open sandwich fluoroimmunoassay (OS-FIA). 
Such genetically encoded FRET-based probes could be transferred from plasmid DNA clone to 
the protein probe quickly without need of fluorescence dye labeling. It also processes great 
potential to be expressed in situ or in vivo to monitor biological events without protein 
transfection as a long-term non-invasive reporter. In this study, I develop three kinds of FRET 
probes by fusing antibody variable region or single chain Fv (scFv) to fluorescent protein to 
detect different biomarkers.  
First, a FRET probe for Osteocalcin, also known as bone Gla protein (BGP) as a model for 
small molecule detection was established. Variation of BGP concentration in blood represents 
different clinical condition, thus it could be used as a diagnosis of bone metabolism diseases. To 
image BGP in vitro and also in cellular milieu, a probe pair was constructed by tethering a 
donor fluorescent protein (FP) to the VH fragment, and an acceptor FP to the VL fragment. The 
optimized cyan-yellow FP pair for FRET, CyPet-YPet, was used as a donor and an acceptor, 
respectively. Protein probes were excited at 430 nm in the presence of different concentration of 
BGP. As the concentration of antigen increased, the overall FRET efficiency was obtained by 
the fluorescence intensity ratio increased. Titration curve was obtained by plotting the BGP 
concentration and the fluorescence intensity ratio of Ypet/Cypet. The calculated EC50 was 
comparable to the IC50 value of KTM-219 Fv obtained by indirect competitive phage ELISA 
indicates that the BGP peptide-binding activity of BGP probe was not interfered by the 
incorporation of fluorescence protein in the N-terminal region. This probe is sensitive enough to 
detect clinically relevant BGP concentration. Therefore this assay might provide a quicker 
detection of human BGP and its fragments for diagnosis. As a demonstration of live cell 
imaging, U2OS osteosarcoma cells, which secrete BGP after differentiation into osteoblastoma 
by vitamin D3 stimulation, were observed. After 36 hrs of induction, the cells manifested 
stronger FRET efficiency than the non-induced cells. This result suggests that our probe 
provides an alternative approach to monitor secreted protein from cells directly.  
Serum albumin (SA) was used as a target of large molecule protein probe demonstration. 
The concentration of SA in blood is an indicator to measure the function of liver. Anti- serum 
albumin scFv obtained from a synthetic phage library and indicated that the interaction between 
VH and VL fragments of this antibody is fairly strong to form a stable complex even in the 
absence of antigen. Furthermore, the large molecular dimension of SA may hinder the energy 
transfer when used for OS-FIA probe. Hence, OS-FIA is not a suitable method for SA detection. 
To construct a more universal assay to detect large size/dimension of biomarkers, I designed a 
novel fluoroimmunoassay based on FP-V region fused protein. Two fusion proteins, VH-fused 
donor and VL-fused acceptor were used, while VH (SA) and VL (SA) with stronger affinity 
resulting in higher FRET efficiency without antigen. In order to solve this problem, I covalently 
linked the VH and the VL fragments by introducing two mutations G44C (VH) and Q100C 
(VL), both in the conserved framework region to make a disulfide-stabilized Fv fragment (dsFv) 
introducing minimal perturbation in their structure. The VH-fused donor and VL-fused acceptor 
will form a stable complex and result in high FRET efficiency between the two FPs in the 
absence of antigen. Once the larger molecule antigen is added, the FRET efficiency will be 
decreased, which could be utilized for quantifying antigen. This novel assay using antibody-FP 
fusion FRET probe FP2-dsFv is named as “open flower” fluoroimmunoassay (OF-FIA).  
When VH-fused donor and VL-fused acceptor complex were stabilized through disulfide 
bond, extremely high FRET efficiency due to the dimerization of fluorescent donor and acceptor 
was observed. This effect results in much higher ∆FRET index (13.5 to 3.5) than other FRET 
probes. FP2-dsFv probe guarantee that the concentrations of donor and acceptor are the same 
which reduce the variation form different detections. The effect of human serum albumin (HSA) 
on overall FRET efficiency was represented by the fluorescence intensity ratio of Ypet/Cypet. 
The binding of large SA would separate the interacting FP pair apart, thus the energy transfer 
between the two FPs would be reduced. The calculated IC50 was 32.8 ±1.0 μM, and the limit of 
detection (LOD) was 0.55 μM. Although the sensitivity of FP2-dsFv SA probe is modest 
compared with other scFv-fused FRET probes, the working range is wider. The IC50 for human 
serum albumin is sufficient to distinguish its normal range (500-800 μM) in serum.  
A novel genetically encoded Quench-based antibody probe could be constructed by 
introducing Y145W/H148V mutations to acceptor fluorescent protein in FP2-dsFv(SA) probe. 
The Y145W/H148V Ypet (dark Ypet) received energy form Cypet but emited weak 
fluorescence as a quencher. Genetically encoded Quenchbody demonstrated antigen-dependent 
fluorescence enhancement, as observed for the conventional Quenchbodies labeled with organic 
dye(s).  
The third probe is a FRET-based probe for quantifying the histone modification level in 
living cells. Post-translational histone modifications including acetylation and methylation at the 
N-terminal tails are the major regulator of gene expression. Abnormal histone modifications 
cause the repression of tumor suppressor gene or activation of oncogene, thus they are also 
biomarkers of carcinogenesis. Nowadays, histone modifications are usually detected by 
immunostaining or activity assay of histone modification enzymes in vitro. The conventional 
assays could not provide enough information about temporal and spatial dynamic changes in 
living cells and organisms. Two research groups have reported FRET-based probes to monitor 
the dynamic changes of histone modification in a single cell. The general design of FRET-based 
probes mentioned above is that fusing a substrate peptide or protein of histone modifying 
enzymes to modification binding protein as a sensor and FRET fluorescent protein pair in 
N-terminal and C-terminal ends as a reporter. However, the dissociation constant Kd of 
FRET-based probes are around 1-200 μM, which means they could barely binding to 
endogenous histone. In addition, many modification binding proteins are not specific enough, 
and can bind several modification sites. Taken together, those FRET-based probes reflect the 
activity of histone modifying and demodifying enzymes, but they are incompetent to monitor 
the modification of specific site.    
A getically encoded histone modification fluorescent probe, modification-specific 
intracellular antibodies (mintbodies), was recently developed. The probe has succeeded in 
monitoring histone acetylation level in cultured cells and living organisms by measuring the 
fluorescence intensity of GFP in the nucleus. In this study, I applied mintbody strategy to 
construct a FRET-based histone modification sensor. The FRET probe is composed of YFP at 
the N-terminal of ScFv for acetyl H3K9, and tethered CFP with histone H3 tail at the 
C-terminus. Once the histone H3 tail is acetylated, it would bind to the single chain Fv to trigger 
the probe’s conformational change. Therefore, the histone acetylation level would be estimated 
by FRET efficiency. 
To verify the validity, probe-transfected U2OS cells were used as a model. The FRET 
efficiency of transfected cells treated with or without histone deacetylase inhibitior, trichostatin 
A (TSA), was measured by fluorescence microscopy. The FRET efficiency is lower in 
cytoplasm than nucleus even without TSA treatment. In nucleus, FRET efficiency increased 
when the cells were treated with TSA. On the contrary, FRET efficiency was not changed in 
cytoplasm. The results mentioned above indicates that the intrabody-based FRET probes could 
measure histone H3K9 acetylationn levels in cultured cells by quantifying FRET efficiency.  
In order to elucidate whether our probe is able to detect the acetylation level of endogenous 
histone or only the activity balance of histone modifying enzyme, H3Lys9 in the C-terminal 
ends of our probe was mutated into Ala and Gln. K9A mutant peptide could not be acetylated 
thus we could exclude the effect of acetylation at H3K9 peptide of the probe. K9Q is an 
acetyl-Lys mimic mutant to compare the basal FRET efficiency. The FRET efficiency of cells 
transfected with different probe was measured in a time-lapse after challenging with high 
concentration of TSA. As a result, FRET efficiency and fluorescence intensity in nucleus 
increased time dependently for all types of probes. It suggests that our probe directly associates 
with endogenous histone tails rather than binds to its own tail. Wild type probes displayed the 
highest response to TSA. This might be resulted from the acetylation of H3 peptide of the probe 
and endogenous histone simultaneously. This probe is the first genetically encoded single chain 
FRET probe which utilize scFv as a sensing domain and also the first probe that visualize the 
modification of endogenous protein in single cell level.  
In summary, this study demonstrated three types of genetically encoded antibody-based 
FRET probes which provide universal approaches to detect different kinds of biomarker in 
homogeneous condition. The amount of analytes could be estimated by FRET efficiency. These 
probes will have a great potential as a diagnostic reagent and provide a simple approach to 
monitor cellular differentiations and epigenetic changes at the single cell level. 
 
